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Abstract 16 
Objective: To establish the prevalence of Type D personality in patients with somatic 17 
symptoms and related disorders and to evaluate the association of Type D personality with 18 
treatment outcomes. This study explores the effect of Type D personality and its two traits, 19 
NA and SI. 20 
Methods: In this longitudinal observational cohort study, we assessed the prevalence of Type 21 
D in 212 patients presenting themselves at a clinic in Tilburg, the Netherlands. We explored 22 
psychological and physical treatment outcomes of a multimodal treatment tailored to patient 23 
needs in relation to Type D scores. We explored the differences with regard to physical 24 
symptoms, anxiety, and depression. We also explored the differences between patients with 25 
and without Type D personality who completed treatment with regard to the baseline scores 26 
of physical symptoms, anxiety, and depression. We explored the association between Type D 27 
personality and treatment outcome using the traditional dichotomous method and the 28 
dimensional method (with main effects of NA and SI, and the interaction of NAxSI).  29 
Results: Of the 212 patients with SSRD, those with Type D personality (181: 61.8%) had 30 
experienced significantly higher levels of depression ( 185 =  4.404,  <  .001) and 31 
anxiety ( 122.22 = 3.757,  <  .001). Of the 212, 187 patients completed treatment. 32 
Mean scores improved significantly for the whole patient group after treatment with regard to 33 
depression  <  .001, anxiety  <  .001, and physical symptoms  <  .001. At 34 
baseline, patients with Type D personality had significantly higher scores in anxiety  35 
(! 1, 185 =  15.707,  < .001) and depression(! 1, 185 =  19.392,  < .001) than 36 
patients without Type D personality who completed treatment. After controlling for the high 37 
baseline scores with regard to physical symptoms, anxiety, or depression, only the effect of 38 
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Type D personality on remission of anxiety was significant #$ =  .33,  =  .039. Neither 39 
NA and SI nor the interaction of NAxSI was associated with the treatment outcome.  40 
Conclusions: This study shows that Type D personality occurs frequently in patients with 41 
SSRD. Type D personality only decreases the probability of remission of anxiety as a 42 
treatment outcome, and both NA and SI play a role in this. Type D personality did not 43 
decrease remission either of physical symptoms or of depression. Hence both NA and SI 44 
factors may be expressions of anxiety mostly in type D.   45 
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1 INTRODUCTION 46 
Background 47 
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM) 48 
includes Somatic Symptom and Related Disorders (SSRD)1, which replaces the Somatoform 49 
Disorders section of the DSM-IV-TR2. The SSRD classification has as a common feature: the 50 
prominence of somatic symptoms associated with significant distress and impairment, 51 
irrespective of the question of whether the somatic symptoms co-occur with a diagnosed 52 
chronic medical condition1. As such, SSRD has a broader scope than have the former 53 
somatoform disorders, which were exclusively linked to the concept of somatization3 (i.e., 54 
having the tendency to experience and communicate psychological distress in the form of 55 
somatic symptoms and to seek medical help for them).  56 
The experience of somatic symptoms in somatization has been associated with harm 57 
avoidance and negative affectivity (NA)4. Compared to non-somatizing patients, patients with 58 
somatization show more self-defeating, depressive, and passive-aggressive personality traits 59 
and neuroticism, and less agreeableness and extraversion5. 60 
A personality construct that might be relevant in SSRD is Type D personality. This 61 
construct combines two traits: NA, the tendency to experience negative emotions across time 62 
and situations6,7; and social inhibition (SI)6, the tendency to inhibit the expression of 63 
emotions and behaviors in social interactions to avoid disapproval8. Individuals with high 64 
levels of both NA and SI are classified as individuals with Type D (i.e., distressed) 65 
personality6. Previous studies showed a prevalence range of 21% - 33%6, 9 of Type D 66 
personality in the general population, 28-53%6 in the population of people with cardiac 67 
diseases or disorders, 36% in people with tinnitus10, 43% in people with chronic pain11, and 68 
57% in people with fibromyalgia12.  69 
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In the populations of people with cardiac diseases, Type D personality is associated with 70 
emotional distress, such as anxiety and depression9, 13, poor health status and quality of life, 71 
myocardial infarcts, and high mortality rates14, high utilization of health services9, poor self-72 
management13, and higher levels of anxiety and depression after cardiac rehabilitation 73 
compared to patients without Type D personality15. An earlier study explored the influence of 74 
SI and NA separately and reported that NA is primarily associated with poorer treatment 75 
outcomes in people with fibromyalgia.12 The prevalence of Type D personality in patients 76 
with fibromyalgia was 56.5%. Furthermore, worse mental and physical health was associated 77 
with NA.12   78 
A systematic review focusing on other patient populations, such as patients with chronic 79 
pain and traumatic brain injuries, found an association of Type D personality with negative 80 
emotions (i.e. depression and anxiety), poor treatment adherence, and an increased number or 81 
severity of reported health symptoms.16 However, the prevalence of Type D personality in 82 
SSRD, and the association with treatment outcome is unknown. 83 
Rationale 84 
Taking the abovementioned into account, the prevalence of Type D personality in patients 85 
with SSRD is unknown. Furthermore, patients with SSRD and Type D personality might 86 
benefit less from treatment than would patients with SSRD who do not have Type D 87 
personality. However, to date no published studies have investigated the prevalence of Type 88 
D personality in SSRD patients, or its association with treatment outcomes. This study aims 89 
to explore this. Because the dichotomous conceptualization of Type D personality construct 90 
has been questioned,17,18 we also explore the effect of NA and SI both separately and 91 
combined in order to establish if one of the factors composing Type D might be more 92 
relevant to treatment outcomes. 93 
In re i
w
6 
 
Objectives 94 
(1) to assess the prevalence rate of Type D personality in patients with SSRD;  95 
(2) to determine the association between Type D personality and physical and psychological 96 
treatment outcomes in patients with SSRD.  97 
(3) To explore the effect of NA and SI separately and as an interaction (NA×SI) on physical 98 
and psychological treatment outcomes.  99 
We hypothesized a higher prevalence of Type D personality in patients suffering from 100 
SSRD compared to previous studies in other patient groups. We also hypothesized that 101 
patients with Type D personality had worse physical and psychological treatment outcomes 102 
than had patients without Type D personality because previous studies showed that Type D 103 
personality was associated with an increased experience of symptoms. In view of previous 104 
research, we hypothesized that the association between NA and treatment outcomes would be 105 
worse than the association between SI or NA×SI and treatment outcomes would be. 106 
2 METHODS AND MATERIALS 107 
2.1 Study design 108 
This study used the longitudinal observational method in a clinical setting. The cohort 109 
consisted of outpatients with SSRD who were treated at the Clinical Centre of Excellence for 110 
Body, Mind, and Health (Dutch abbreviation: CLGG), a department for treatment of complex 111 
SSRD of GGz Breburg, a specialty mental health institution (SMHI) in Tilburg, the 112 
Netherlands. CLGG uses computerized Patient Routine Outcome Monitoring (PROM; 113 
assessed every six weeks), which consists of a set of questionnaires that give an indication of 114 
the severity and frequency of the symptom(s)19. For this study, we used a selection of the 115 
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PROM questionnaires at baseline and at the end of treatment. Consecutive patients who had 116 
been referred to CLGG between August 2013 and April 2016 were included in the study. 117 
Patients are referred to CLGG by general practitioners, by medical specialists from general 118 
hospitals, or by psychiatrists working in Psych Med units of general medical hospitals or in 119 
SMHIs. They have been suffering from somatic symptoms causing high levels of distress for 120 
an average of eight years and six months and have received treatment for their condition 121 
without solace for an average of seven years. They suffer from highly complex SSRD as 122 
established in earlier research by this group.20  123 
All patients were informed before intake that the PROM data pertaining to their treatment 124 
could be used on an anonymous basis for research, and that they could indicate during the 125 
intake if they declined the use of their data for scientific purposes. If the patient declined, this 126 
was recorded in the administration system and the data of these patients were excluded from 127 
the study. No consent regarding the use of their data for scientific purposes did not have any 128 
consequences for treatment at our center. The study protocol was approved by the scientific 129 
committee of GGz Breburg (file number: CWO 2014-11). 130 
2.2 Participants  131 
Patients of 18 years of age or older who completed the intake and baseline PROM 132 
measures were evaluated for eligibility. Patients were excluded if they were engaged in 133 
personal or professional injury procedures (e.g., work-related lawsuits), had an IQ below 80 134 
as assessed with the Dutch Adult Reading Test21 or were, for whatever reason, unable to 135 
follow treatment at CLGG.  136 
2.3 Treatment 137 
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After the intake, treatment options at CLGG were offered to the patients in a Shared 138 
Decision Making (SDM) model.19 CLGG offers a multimodal treatment that builds on 139 
treatment modes suggested in the multidisciplinary guideline for medically unexplained 140 
symptoms and somatic disorders,22,23 such as acceptance and commitment therapy (ACT), 141 
cognitive behavioral therapy (CBT), and problem-solving treatment (PST) provided by 142 
trained and supervised psychologists sequentially, depending on patients’ preferences and 143 
needs. This was provided in combination with psychiatrist- or physician-prescribed 144 
pharmacotherapy focusing on chronic pain24 or comorbid depressive or anxiety disorders. 145 
Every three months, both psychotherapeutic and pharmacotherapeutic treatment were 146 
adjusted based on progress in terms of PROM and using the SDM model with the patient,19 147 
after multidisciplinary team consultations. A pilot study evaluating this treatment model 148 
showed high compliance among patients.19 On average, patients were treated for one year 149 
according to this multimodal treatment model. 150 
2.4 Instruments 151 
2.4.1 Patient characteristics.  152 
Sociodemographic variables included age, education level, and gender. Educational level 153 
was classified following Verhage.25 For this study, we dichotomized educational level due to 154 
the relatively small sample of patients who completed treatment. Educational level was 155 
categorized as follows: the five lowest classifications were classified as “low” and the two 156 
highest classifications were classified as “high.” DSM-5 SSRD diagnoses were established by 157 
two psychiatrists after psychiatric interview.  158 
2.4.2 Questionnaire assessment. 159 
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The standard intake procedure at the CLGG consists of a questionnaire assessment during 160 
intake (referred to as baseline measurement), a case history assessment, a physical 161 
assessment, a psychiatric evaluation, and a psycho-diagnostic assessment. The DS14 162 
Questionnaire (DS14)6 was self-administered during the psycho-diagnostic assessment at 163 
intake. 164 
2.4.2.1 Type D personality 165 
Type D personality was measured at intake by means of the Type D scale 14 (DS14).6 166 
This self-report questionnaire consists of two seven-item subscales: one scale that assesses 167 
NA and another that assesses SI. Items were scored on a 5-point Likert scale having a range 168 
of 0 (false) through 4 (true). Total scores on each of the two subscales can range from 0 to 28, 169 
with higher scores indicating higher levels of NA and/or SI. The DS14 has good 170 
psychometric properties.6 Individuals who score at least 10 on each of the subscales are 171 
classified as having a Type D personality.6 This means that the Type D personality is 172 
conceived as a dichotomous typology. The typology may be useful from a clinical 173 
perspective where dichotomous treatment decisions have to be made.  174 
2.4.2.2 Physical symptoms 175 
The Physical Symptom Checklist (PSC)26 is a 51-item self-report questionnaire that 176 
measures physical symptoms during the last week. The score descriptions are as follows:  0, 177 
does not burden me; 1, sometimes burdens me; 2, often burdens me; and 3, often burdens me. 178 
We followed the guidelines of Van Hemert,26 in which the item scores were converted into 179 
dichotomous scores. Scores of 0 and 1 were transformed to 0, and scores of 2 and 3 were 180 
transformed to 1. In this way, a symptom is present when rated a 2 or 3. The total score 181 
represents the number of symptoms that were present in the last week. Total scores ranged 182 
from 0-51. A higher score on the PSC indicates a higher number of symptoms present in the 183 
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last week26. The PSC is a valid Dutch questionnaire to assess physical symptoms27. However, 184 
no validated cut-off scores are present. The mean score for patients visiting the general 185 
practitioners office equaled six for women and four for men.28 Regarding these mean scores 186 
of the PSC in a general practitioner’s sample, we defined treatment remission as a score of 187 
below 5 at the end of treatment. 188 
2.4.2.3 Anxiety  189 
To assess anxiety symptoms, the Generalized Anxiety Disorder questionnaire (GAD-7) 190 
was used. The GAD-7 is a 7-item self-report questionnaire that measures symptoms of 191 
anxiety during the last two weeks. For each item, scores range from 0 (not at all) to 3 (nearly 192 
every day)29. Total scores range from 0 to 21, with higher scores indicating higher levels of 193 
anxiety symptoms. The GAD-7 is a reliable questionnaire29,30 and has been adapted in Dutch 194 
and well-validated in the Netherlands.31,32  195 
2.4.2.4 Depression 196 
To assess depression, the Patient Health Questionnaire-9 (PHQ-9)33 was used. The PHQ-9 197 
is a 9-item self-report questionnaire. For each item, scores range from 0 (not at all) to 3 198 
(nearly every day). Total scores range from 0 to 27, with higher scores indicating higher 199 
levels of depressive symptoms.33 The PHQ-9 has been shown to be a reliable 200 
questionnaire33,34 and has been adapted in Dutch and well-validated in the Netherlands.34  201 
2.5 Treatment outcomes 202 
2.5.1 Remission 203 
For each of the outcome measures (PSC, GAD-7, and PHQ-9) remission on a single 204 
outcome was defined as having a score that dropped below 5 after treatment.35 Remission of 205 
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symptoms is defined as the point after treatment at which a patient’s score that had exceeded 206 
the clinical cutoff at baseline no longer exceeds it.  207 
2.5.2 Treatment response 208 
Response is defined as a reduction of the score (on the PSC, the GAD-7, or the PHQ-9) of at 209 
least 50% after the therapy compared to the score at intake, as defined similarly in earlier 210 
studies.36,37 211 
2.6 Statistical methods           212 
To describe patient characteristics and the prevalence of Type D personality, we obtained 213 
descriptive statistics. To test whether the Type D personality group and the non-Type D 214 
personality group differed on baseline characteristics, we executed independent t-tests and 215 
Chi-square tests. Cohen’s d was used to gauge the effect size. Effect sizes of about d = 0.2 are 216 
considered small, those of about d = 0.5 are medium, and those of d ≥ 0.8 are large.38 For the 217 
PSC, the GAD-7, and the PHQ-9, we also studied mean differences between raw scores 218 
before and after treatment. Paired-sample t-tests were conducted to test if patients who 219 
completed treatment had, on average, significant lower physical, anxiety, and depressive 220 
symptoms at the end of treatment. Unpaired t-tests were done for the Type D and non-Type D 221 
groups separately. Using the McNemar test, we also inspected the proportion of patients 222 
having a clinical diagnosis to see changes between intake and after the treatment. We also 223 
performed an Analysis of Variance (ANOVA) for all outcomes of interest with Type D 224 
personality as a between-subject factor for patients who completed treatment. 225 
Regarding the third objective, to study the hypothesized relationship of Type D personality 226 
with the dichotomous outcome variables, we used two different analyses. The first analysis 227 
used the operationalization of Type D as described by Denollet et al. (2005). This method 228 
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uses cutoff scores for the two subscales of Type D, i.e. NA and SI, and we combined them to 229 
determine a categorical classification of patients as having Type D or non-Type D. We fitted 230 
Model 1, which included the background variables of age, gender, and education level; in 231 
Model 2 we added the dichotomous Type D variable as predictor; and in Model 3 we 232 
controlled for baseline measures of the outcome measurement of interest, namely the PSC, 233 
the GAD-7, or the PHQ-9. These results are shown in Table 3. 234 
In the second analysis, we explored the extent to which NA, SI, and their interaction 235 
(NA×SI) predicted treatment outcomes. For this approach, the following three models were 236 
applied. Model 1 included the background variables of age, gender, and education level; 237 
Model 2 added the variables NA and SI (i.e., main effects only); and Model 3 added the 238 
interaction term between NA and SI, denoted NA×SI. Significant findings were controlled 239 
for the measurement of interest using the baseline measurement of the PSC, the GAD-7, or 240 
the PHQ-9 by using a model in which this baseline measurement was added. These results are 241 
shown in Table 4. 242 
Likelihood ratio tests were used to see whether model fit improved when adding 243 
predictors. Nagelkerke’s pseudo R-square was used to gauge the effect sizes. Following 244 
Nagelkerke,39 we interpreted the pseudo R-square as the proportion of the variation explained 245 
by the model, but we are aware that pseudo R-squares are not the same as R-squares in linear 246 
models. For all models, we used Cohen38 guidelines for the R-squares to interpret 247 
Nagelkerke’s pseudo R-square (i.e., R-square = .02 were considered small, R-square = .13 248 
were considered medium, and R-square ≥ .26 were considered large). All analyses were 249 
performed by means of IBM SPSS statistics 22.40 250 
3. RESULTS 251 
3.1 Sample characteristics 252 
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Figure 1 displays a flow chart of the study. A total of 228 patients completed the DS14 253 
questionnaire at baseline. Of these patients, 16 (7.0%) were not diagnosed as having SSRD 254 
and were excluded from the analyses. Of the remaining 212 patients, 187 (88.2%) patients 255 
completed treatment. Table 1 shows the background characteristics. Of the patients who 256 
completed treatment, 15 (8.0%) were diagnosed with a conversion disorder, 11 (5.9%) with 257 
an illness anxiety disorder, and 161 (86.1%) with a somatic symptom disorder. 258 
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 259 
Figure 1. Flowchart of Patients included in the study. Sample size is given for patients who completed the Treatment and Questionnaire 260 
Assessment. 261 
Abbreviations: ‘DS14’, Type D Scale; ‘SSRD’, Somatic Symptom and Related Disorders; ‘PSC’, Physical Symptom Checklist; ‘GAD-7’, 262 
Generalized Anxiety Disorder; ‘PHQ-9’, Patient Health Questionnaire.  263 
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3.2 Baseline characteristics  264 
Table 1 shows the baseline characteristics for the SSRD patients for the total sample and 265 
for patients who completed the treatment. The prevalence of Type D personality in the total 266 
sample was 61.79% (n = 131). Type D patients did not differ significantly from non-Type D 267 
patients with respect to age, gender, and educational level. Compared to the non-Type D 268 
patients, patients with Type D personality experienced significantly higher levels of 269 
depression ( 210 = 4.481,  <  .001, mean difference 3.70, 95% (): 2.07 − 5.33) and 270 
anxiety ( 144.01 = 4.063,  <  .001, mean difference 3.16, 95% (): 1.62 − 4.69 ) at 271 
intake. Patients with Type D personality and without Type D personality did not differ 272 
significantly with regard to physical symptoms at baseline. A total of 81 patients (43.3%) had 273 
a chronic medical condition. 274 
Further exploration of medical conditions showed that one patient was diagnosed with 275 
hypertension, eight were diagnosed with cardiovascular disease, one was diagnosed with 276 
rheumatoid arthritis, four were diagnosed with diabetes mellitus, and four were diagnosed 277 
with asthma/chronic obstructive pulmonary disease. With regard to physical comorbidity, 17 278 
(9.1%) patients had no somatic disorder, 116 (62.0%) patients had one somatic disorder, 34 279 
(18.2%) patients had two somatic disorders, 12 (6.4%) patients had three somatic disorders 280 
and eight (4.3%) patients had more than three somatic disorders. 281 
With regard to the patients who completed treatment, the prevalence of Type D 282 
personality was 62.57% (n = 117). No significant differences were found regarding 283 
demographic variables between patients with and without a Type D personality who finished 284 
treatment. Compared to the non-Type D patients, patients with a Type D personality who 285 
finished treatment experienced significantly higher levels of depression ( 185 =286 
 4.404,  <  .001, mean difference 3.89, 95% (): 2.15 − 5.64, and anxiety ( 122.22 =287 
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3.757,  <  .001, mean difference 3.12, 95% (): 1.48 − 4.77 at intake. Demographic 288 
characteristics did not differ significantly between patients who completed treatment and the 289 
total sample of patients. Fourteen (56.0%) of the 25 patients who did not complete treatment 290 
had a Type D personality.  291 
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  292 
Table 1  
Sociodemographic Variables, Predictors and Outcome Variables of the Total Sample of Patients with and without Type D Personality and of 
Patients with and without Type D Personality Who Completed Treatment, at Baseline.  
  Total sample (n = 212)  Patients who completed treatment (n = 
187) 
 Total 
(N =212) 
Type D 
(n = 131) 
Non-Type D 
(n = 81) 
 Total 
(N = 187) 
Type D 
(n = 117) 
Non-Type D 
(n = 70) 
 
Sociodemographic 
variables 
M (SD) / n 
(%) 
M (SD) / n 
(%) 
M (SD) / n 
(%) 
p M (SD) / n (%) M (SD) / n 
(%) 
M (SD) / n 
(%) 
p 
Gender (male) 82 (38.67%) 56 (42.75%) 26 (32.10%) .122a 72 (38.50%) 50 (42.74%) 22 (31.43%) .124a 
Age in years 42.51 (12.43) 41.26 (11.53) 44.54 (13.58) .061b 42.34 (12.36) 41.15 (11.37) 44.31 
(13.70) 
.091b 
Education level (low) 57 (26.89%) 36 (27.48%) 21 (25.93%) .804a 49 (26.20%) 30 (25.64%) 19 (27.14%) .821a 
DS14 total 31.70 (12.15) 38.94 (8.24) 19.99 (7.39) <.001b 31.87 (12.34) 39.19 (8.21) 19.65 (7.42) <.001b 
Negative affectivity 17.94 (6.59) 20.73 (4.77) 13.44 (6.65) <.001b 17.90 (6.71) 20.89 (4.74) 12.89 (6.56) <.001b 
Social inhibition 13.76 (7.51) 18.21 (5.46) 6.56 (3.93) <.001b 13.98 (7.49) 18.30 (5.50) 6.76 (3.97) <.001b 
PSC 16.89 (8.00) 17.67 (8.13) 15.63 (7.65) .071b 16.84 (7.99) 17.58 (7.88) 15.60 (8.05) .101b 
GAD-7 11.78 (5.45) 13.00 (4.79) 9.83 (5.89) <.001b 11.80 (5.42) 12.97 (4.76) 9.84 (5.90) <.001b 
PHQ-9 14.34 (6.10) 15.75 (5.67) 12.05 (6.11) <.001b 14.24 (6.13) 15.69 (5.71) 11.80 (6.08) <.001b 
Abbreviations: ‘M’, mean; ‘SD’, standard deviation; ‘DS14’, Type D Scale 14; PSC’, Physical Symptom Checklist; ‘GAD-7’, Generalized 
Anxiety Disorder; ‘PHQ-9’, Patient Health Questionnaire. 
Note: PSC, GAD-7, and PHQ-9 are displayed as mean scores at intake. 
a
 Pearson Chi-Square test 
b
 Students t-test 
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3.3 Treatment outcomes 293 
3.3.1 Mean changes from baseline 294 
The 187 patients who completed treatment showed a significant mean change of scores on 295 
the PSC (M = 16.77, SD = 7.80) and after treatment ((M = 13.43, SD = 9.66),  122 =296 
 4.786,  <  .001. A significant mean change was also found between the mean scores on 297 
the GAD-7 at baseline (M = 11.73, SD = 5.24) and after treatment ((M = 9.02, SD = 6.40), 298 
 122 =  5.969,  <  .001. A significant mean change was also found between the PHQ-299 
9 at baseline (M = 14.30, SD = 6.10) and after treatment ((M = 11.26, SD = 7.45),  124 =300 
 5.758,  <  .001). ANOVA showed that scores for anxiety (! 1, 185 =  15.707,  <301 
.001) and depression (! 1, 185 =  19.392,  < .001) were higher for patients with Type D 302 
personality compared to patients without Type D personality at baseline. Scores regarding 303 
physical symptoms did not differ significantly at baseline (! 1, 185 =  2.722,  =  .101 304 
but ANOVA with baseline measures as covariates showed that anxiety (! 1, 120 =305 
 70.379,  <  .001) and depression (! 1, 122 =  67.425,  < .001) scores at baseline 306 
explained these significant findings. Table 2 shows the frequencies and percentages of 307 
patients who scored above the clinical cutoff on the PSC, GAD-7, and PHQ-9 before and 308 
after treatment. Results show that 93.5% had burdensome physical symptoms; 90.2% had 309 
clinical anxiety; and 96% of the patients were clinically depressed at intake. These 310 
percentages dropped significantly by 13.8% for physical symptoms, 21.1% for anxiety, and 311 
20.0% for depression.  312 
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Table 2 
Frequencies and Percentages of Patients Who Scored Above/Below Cutoff at Intake and at 
End of Treatment. 
Questionnaire  
 
Intake Assessment  End of Treatment 
Assessment 
Change McNemar 
Test 
  Below 
Cutoff 
Above 
Cutoff 
 Below 
Cutoff 
Above 
Cutoff 
  
 N n (%) n (%)  n (%) n (%)  P 
PSC 123 8 (6.5) 115 
(93.5) 
 25 (20.3) 98 (79.7) 13.8% <.001 
GAD-7 123 12 
(9.8) 
111 
(90.2) 
 38 (30.9) 85 (69.1) 21.1% <.001 
PHQ-9 125 5 (4.0) 120 
(96.0) 
 30 (24.0) 95 (76.0) 20.0% <.001 
Abbreviations: ‘PSC’, Physical Symptom Checklist; ‘GAD-7’, Generalized Anxiety 
Disorder; ‘PHQ-9’, Patient Health Questionnaire. Cutoff scores were 5 for each scale. 
  314 
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3.4 Hierarchical regression analyses 315 
3.4.1 Predicting treatment outcome from Type D personality.  316 
3.4.1.1 Remission of symptoms 317 
Table 3 shows the results of the logistic regression analyses for predicting remission and 318 
response from the dichotomous conceptualization of Type D personality. Type D personality 319 
had a significant negative effect on remission of anxiety (#$ =  .29,  =  .009; Nagelkerke 320 
equaled 8.8%; -.1 = 6.931,  =  .008) which was retained after controlling for baseline 321 
scores for anxiety (#$ =  .33,  =  .039; Nagelkerke equaled 25.3%; -.1 = 22.732,  <322 
.001). Type D personality had a significant negative effect on remission of depression 323 
(#$ =  .21,  =  .001; Nagelkerke equaled 12.9%; -.1 = 10.665,  =  .001) but after 324 
we controlled for baseline scores for depression, this effect was not significant (#$ =325 
 .36,  =  .065; Nagelkerke equaled 24.1%; -.1 = 22.732,  < .001). Type D personality 326 
was not associated with a remission of physical symptoms. These results suggest that the 327 
presence of Type D personality decreases the probability of a remission of anxiety and 328 
depression but not a remission of physical symptoms. When we controlled for baseline scores 329 
for the outcome of interest, the effect on remission of anxiety remained significant. 330 
3.4.1.2 Treatment response of symptoms 331 
Regarding response, the results show that Type D personality had a significant effect on 332 
response of physical symptoms (#$ = .38,  = .021;  Nagelkerke equaled 6.2%; -.1 =333 
5.396,  = .020, but after we controlled for baseline scores for physical symptoms, this 334 
effect was not significant (#$ = .44,  = .059; Nagelkerke equaled 9.1%; -.1 =335 
8.298,  =  .004). Type D personality was not associated with a response of anxiety and 336 
depression. These results suggest that the presence of Type D personality decreases the 337 
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probability of a response of physical symptoms but not a response of anxiety and depression. 338 
However, the significant effect of Type D personality on physical symptoms disappeared 339 
after the baseline scores on the PSC were controlled for.340 
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 342 
Table 3 
Logistic Regression Predicting Remission or Response from Type D Personality. 
  Outcome Variables 
  Physical Symptoms (PSC)  Anxiety (GAD-7)  Depression (PHQ-9) 
             
  OR 95% CI ∆R2d  OR 95% CI ∆R2d  OR 95% CI ∆R2d 
  Results for Remission 
Model 1a   .076    .009    .035 
             
Model 2b    .044    .088*    .129* 
    Type D  .38 [.13; 1.10]   .29* [.12; .73]   .21* [.08; .55]  
Model 3c    .196    .253*    .241 
    Type D  .58 [.18; 1.87]   .33*    .36 [.13; 1.06]  
  Results for Response 
Model 1a   .010    .010    .002 
             
Model 2b    .062*    .040    .032 
   Type D  .38* [.17; .86]   .45 [.19; 1.07]   .49 [.22; 1.12]  
Mode 3c    .091    .067    .020 
   Type D  .44 [.19; 1.03]   .54 [.22; 1.30]   .58 [.25; 1.38]  
Abbreviations: ‘PSC’, Physical Symptom Checklist; ‘GAD-7’, Generalized Anxiety Disorder; ‘PHQ-9’, Patient Health 
Questionnaire; ‘OR’, Odds Ratio; ‘95% CI’, 95% Confidence Interval. 
Notes: a Model 1 included background variables age, gender, and education level. b Model 2 included the variables of Model 1 and 
added the dichotomous variable for Type D personality. c Model 3 included the variables of Model 1 and Model 2 and added the 
baseline measurement for outcome of interest (PSC, GAD-7, or PHQ-9). d Nagelkerke’s Pseudo R-square. All coefficient marked by 
an * are significant at the 5% significance level. 
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3.4.2 Predicting treatment outcome on the various outcome measures from NA, SI, and their 343 
interaction.  344 
Table 4 shows the results of the logistic regression analyses for predicting remission and 345 
response from NA, SI, and NA×SI per outcome measure.  346 
3.4.2.1 Remission of symptoms 347 
The results for the remission (upper panel) of physical symptoms are as follows: NA had a 348 
significant effect on remission of physical symptoms (#$ = .85,  = .002; and Nagelkerke 349 
equaled 16.4% (-.2 = 12.372,  =  .002.  The results for the remission of anxiety and 350 
depression followed the same trend: NA had a significant effect on the remission of anxiety 351 
(#$ = .85,  = .001; Nagelkerke equaled 17.3% (-.2 = 14.029,  =  .001), and NA had 352 
a significant effect on the remission of depression (#$ = .91,  = .028; Nagelkerke equaled 353 
15.4% (-.2 = 12.783,  = .002). After we controlled for baseline scores, these effects 354 
were not significant for physical symptoms (#$ = .90,  = .082; Nagelkerke equaled 11.0%; 355 
-.1 = 9.080,  =  .003), for anxiety (#$ = .92,  = .115; Nagelkerke equaled 15.5%; 356 
-.1 = 14.364,  < .001), and for depression (#$ = .99,  = .890; Nagelkerke equaled 357 
20.1%; -.1 = 19.057,  < .001). SI did not show any significant effect on the remission 358 
of the outcome measures. These results suggest that if levels of NA are elevated, the 359 
probability of remission of physical symptoms, anxiety, and depression decreases, but this 360 
effect disappears when baseline scores are controlled for. NA×SI was not associated with the 361 
remission of physical symptoms, anxiety, or depression. 362 
3.4.2.2 Treatment response of symptoms 363 
The results for response (lower panel) showed that NA had a significant effect on response 364 
of physical symptoms (#$ = .91,  = .016; Nagelkerke equaled 10.9% (-.2 = 9.580,  =365 
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.008). NA also had a significant effect on the treatment response on anxiety (#$ = .89,  =366 
.007; Nagelkerke equaled 11.3% (-.2 = 9.626,  =  .008). After we controlled for 367 
baseline scores, these effects were not significant for physical symptoms (#$ = .94,  =368 
.125; Nagelkerke equaled 5.9%; -.1 = 5.571,  = .018) and for anxiety (#$ = .91,  =369 
.065; Nagelkerke equaled 1.9%; -.1 = 1.661,  =  .198). No significant associations were 370 
found regarding the response of depression. SI did not show any significant effects on the 371 
treatment responses for the outcome measures. These results suggest that if the levels of NA 372 
are elevated, the probability of response of physical symptoms and anxiety decreases. 373 
However, these effects disappeared when baseline scores were controlled for. NA×SI was not 374 
associated with a response of physical symptoms, anxiety, or depression.  375 
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Table 4 
Logistic Regression Predicting Remission or Response from Type D Personality Dimensions. 
  Outcome Variables 
  Physical Symptoms (PSC)  Anxiety (GAD-7)  Depression (PHQ-9) 
  OR 95% CI ∆R2e  OR 95% CI ∆R2e  OR 95% CI ∆R2e 
 Results for Remission 
Model 1a   .076    .009    .035 
             
Model 2b    .164*    .173*    .154* 
    SI  1.03 [.94; 1.13]   1.01 [.94; 1.08]   .94 [.87; 1.02]  
    NA  .85* [.77; .94]   .85* [.77; .94]   .91* [.84; .99]  
Model 2d    .110    .155    .201 
   SI  1.01 [.91; 1.11]   1.00 [.93; 1.08]   .95 [.87; 1.04]  
   NA  .90 [.81; 1.01]   .92 [.82; 1.02]   .99 [.90; 1.10]  
Model 3c    .062    .024    .003 
    SI  1.45 [1.00; 2.10]   1.22 [.92; 1.62]   1.00 [.79; 1.26]  
    NA  1.07 [.83; 1.38]   .97 [.79; 1.18]   .94 [.81; 1.10]  
    NA×SI  .98 [.96; 1.00]   .99 [.98; 1.00]   1.00 [.99; 1.01]  
 Results for Response 
Model 1a   .010    .010    .002 
             
Model 2b    .109*    .113*    .058 
    SI  .98 [.92; 1.05]   1.00 [.94; 1.07]   .95 [.90; 1.02]  
    NA  .91* [.85; .98]   .89* [.81; .97]   .97 [.90; 1.04]  
Model 2d    .125    .019    .008 
   SI  .98 [.91; 1.04]   1.00 [.94; 1.07]   .96 [.90; 1.02]  
   NA  .94 [.87; 1.02]   .91 [.83; 1.01]   .98 [.91; 1.07]  
Model 3c    .009    .010    .003 
    SI  1.08 [.88; 1.33]   1.13 [.88; 1.44]   1.00 [.81; 1.21]  
    NA  .97 [.84; 1.12]   .96 [.80; 1.14]   1.00 [.87; 1.13]  
    NA×SI  1.00 [.99; 1.01]   .99 [.98; 1.01]   1.00 [.99; 1.01]  
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Abbreviations: ‘PSC’, Physical Symptom Checklist; ‘GAD-7’, Generalized Anxiety Disorder; ‘PHQ-9’, Patient Health 
Questionnaire; ‘OR’, Odds Ratio; ‘95% CI’, 95% Confidence Interval; ‘SI’, Social Inhibition; ‘NA’, Negative Affectivity; 
‘NA×SI’, interaction term of NA and SI. 
Notes: a Model 1 included background variables age, gender, and education level. b Model 2 included the variables of 
Model 1 and added the variables SI and NA. c Model 3 included the variables of Model 1 and Model 2 and added the 
interaction variable NAxSI. d Model 2d included the variables of Model 1 and Model 2 and added the baseline measurement 
for outcome of interest (PSC, GAD-7, or PHQ-9). e Nagelkerke’s Pseudo R-square. All coefficient marked by an * are 
significant at the 5% significance level.  
376 
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4 DISCUSSION 377 
4.1 Key results 378 
This is the first study exploring the prevalence and association with treatment outcomes of 379 
Type D in patients with SSRD. The results show that the prevalence of Type D personality is 380 
63% of the patients with SSRD who completed treatment, meaning that two out of three 381 
patients report a strong tendency to experience negative emotions and social inhibition. This 382 
prevalence exceeds the percentages reported in studies on Type D personality in various 383 
populations, including the general population9, patients suffering from cardiovascular 384 
disease6, and patients suffering from tinnitus10, chronic pain11, or fibromyalgia12. All patients 385 
had fewer physical, anxious, and depressive symptoms at the end of treatment. However, 386 
after the correction for baseline anxiety and depression, the factor of having Type D 387 
personality significantly decreased only the effect on the remission of anxiety symptoms. NA 388 
and SI or NAxSI did not decrease the effect of the remission of physical symptoms, anxiety, 389 
or depression.  390 
4.2 Interpretation 391 
This finding sheds new light on the association between Type D and anxiety and 392 
depression, as it confirms earlier reports of an association between the three but does not 393 
corroborate earlier findings that NA would be the only associated factor in Type D. 394 
Furthermore, this study still finds a negative effect on anxiety remission on both factors of 395 
Type D, which suggests that the main factor in Type D influencing treatment outcome in 396 
SSRD might be anxiety related. This would mean that the negative affectivity as well as the 397 
social inhibition would be anxiety related, not depression related, in Type D patients.  398 
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Earlier studies also reported not only an association between Type D personality and anxiety 399 
but also between SI and anxiety in the general population.41 Furthermore, the Type D 400 
components of NA and SI were also associated with anxiety42,43 and severity of anxiety44 in a 401 
population of cardiac patients. These results suggest that anxiety may be an influencing factor 402 
with regard to treatment outcomes, and that this factor is worth studying in future research of 403 
patients with SSRD. The finding that Type D personality was not associated with treatment 404 
outcomes regarding physical symptoms in our study may be due to the flooring effect, as 405 
physical symptoms will not subside completely. This may be a case of the presence of 406 
chronic medical conditions. Our study did show that our sample consisted of patients with 407 
substantial physical diseases: 91% of the patients had at least one somatic disorder (e.g., 408 
rheumatoid arthritis, diabetes mellitus, asthma) of which 10% had at least three somatic 409 
disorders.  410 
4.3 Strengths and limitations 411 
A strength of the study is that this is the first study exploring the influence of Type D 412 
personality as well as SI and NA and their interaction, on treatment outcomes of patients 413 
suffering from SSRD. The limitations of the study are, firstly, that it is a non-experimental, 414 
observational design, which prevents causal interpretations. Hence, the results of this study 415 
should be interpreted with caution. Second, the subjects of this study were recruited in an 416 
outpatient SMHI in the Netherlands that is a Clinical Centre of Excellence for SSRD, which 417 
attracts patients with severe disorders. Furthermore, the treatment of patients with SSRD 418 
requires22,23 a standardized, tailored treatment approach that also prohibits a stratification for 419 
each kind of treatment that is provided at our center. Such stratification requires, if possible, a 420 
substantially large sample to preserve power. Nevertheless, this approach, which is in 421 
accordance with multidisciplinary guidelines,22,23 can either consist of numerous 422 
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combinations of ACT and/or CBT and/or PST sessions whether or not combined with a 423 
variety of pharmacological interventions, which renders the needed sample not feasible.  424 
This is a longitudinal observational study that explores the association between Type D 425 
personality and treatment outcomes in patients with SSRD. All patients, both with and 426 
without Type D, received the same, standardized treatment, which consisted of modules of 427 
ACT, CBT and PST, as well as of medication algorithms for pain, depression, or anxiety. 428 
These modules were tailored and delivered based on the patients’ needs and preferences, as 429 
well as on the progress of treatment over time as monitored with PROM. So, although this 430 
was a standardized approach, due to the tailoring, not all patients in the study received 431 
exactly the same treatment modules in the same sequence or containing all elements. This 432 
limitation has to be expected as this is not an experimental design, but an observational 433 
design, and an evaluation of the treatment modules themselves was not an objective of this 434 
study.  435 
It is a limitation of the study that detailed information about medication use was not 436 
provided. Therefore, the influence of medication use as well as drug adherence on treatment 437 
outcome is unknown. This is an interesting subject for future studies. Furthermore, 43% of 438 
the patients in our sample were diagnosed with at least one chronic medical condition. The 439 
influence of these conditions with regard to treatment outcome was not explored so caution 440 
should be exercised when interpreting our findings regarding patients with SSRD and chronic 441 
medical conditions. However, there was no significant association with Type D personality in 442 
patients who followed through on treatment, including drug treatment, and patients who did 443 
not and only a small group did not follow through with treatment (N=25 of which N=14 Type 444 
D). Hence, future research might explore if drug adherence might be influenced by NA or SI 445 
or by Type D personality in general. Nevertheless, it is worthwhile exploring whether or not 446 
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patients with SSRD, Type D personality, and, for instance, cardiovascular diseases benefit 447 
less from treatment compared to patients with SSRD, Type D personality and other chronic 448 
medical conditions. Exploring the feasible negative effect of these cardiovascular diseases in 449 
patients with SSRD regarding treatment outcome should be focus of future studies.   450 
Finally, the results are not stratified for each kind of treatment that is provided at our 451 
center. Future studies should explore the possible difference remission/response of treatment 452 
for each kind of treatment offered to enable conclusions regarding which kind of treatment is 453 
most efficient regarding physical symptoms, anxiety, and depression. Also, treatment 454 
duration per kind of treatment (in days or hours) should also be included in future studies to 455 
evaluate the treatment duration of each specific kind of treatment and their effects on 456 
treatment outcomes. In addition, the effects of pharmacotherapy on symptom remission as 457 
well as the influence of known medical conditions are also worth exploring in this patient 458 
population. 459 
4.3.1 Implications  460 
The implications for clinical practice may be that more attention should be given to Type 461 
D with a specific focus on NA in diagnosis and treatment provision for patients with SSRD. 462 
At present, there are no well-evaluated evidence-based therapies yet that are specifically 463 
designed to alter the combination of NA and SI. Future research should evaluate whether 464 
patients with SSRD and Type D personality may benefit from interventions that address Type 465 
D personality and might improve the well-being and thus the functioning of this difficult-to-466 
treat group of patients. 467 
Treatment of patients with SSRD is challenging since these patients are complex20 and 468 
may be burdened by clinical aspects, such as personality characteristics (such as Type D 469 
personality or alexithymia45) or neurocognitive impairment,46 which may interfere with 470 
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treatment outcomes. These findings corroborate that the treatment of patients with SSRD can 471 
be influenced by multiple factors. Future studies should continue to explore personality 472 
factors and characteristics of patients with SSRD and explore the effects on treatment 473 
outcomes of these characteristics. 474 
Conclusions 475 
The prevalence of Type D personality in patients with SSRD is 63%, which is higher than 476 
in other patient groups. Our results showed that patients had significantly fewer physical 477 
symptoms, anxiety, and depression after treatment. However, the presence of Type D 478 
personality only decreased the remission of anxiety, not of physical symptoms or of 479 
depression. Since Type D personality is associated with anxiety and severity of anxiety, 480 
future studies should explore to see if patients with SSRD and Type D personality may profit 481 
from interventions that include Type D personality.   482 In revi
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